DK1458391T3 - Fremgangsmåde til at behandle bakterielle infektioner ved anvendelse af gemifloxacin eller et salt deraf og et beta-lactamantibiotikum - Google Patents
Fremgangsmåde til at behandle bakterielle infektioner ved anvendelse af gemifloxacin eller et salt deraf og et beta-lactamantibiotikumInfo
- Publication number
- DK1458391T3 DK1458391T3 DK02795444T DK02795444T DK1458391T3 DK 1458391 T3 DK1458391 T3 DK 1458391T3 DK 02795444 T DK02795444 T DK 02795444T DK 02795444 T DK02795444 T DK 02795444T DK 1458391 T3 DK1458391 T3 DK 1458391T3
- Authority
- DK
- Denmark
- Prior art keywords
- gemifloxacin
- beta
- salt
- bacterial infections
- lactam antibiotic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33449501P | 2001-11-30 | 2001-11-30 | |
| PCT/KR2002/002248 WO2003045390A1 (en) | 2001-11-30 | 2002-11-29 | A METHOD OF TREATING BACTERIAL INFECTIONS USING GEMIFLOXACIN OR A SALT THEREOF AND A β -LACTAM ANTIBIOTIC |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1458391T3 true DK1458391T3 (da) | 2008-01-07 |
Family
ID=23307473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02795444T DK1458391T3 (da) | 2001-11-30 | 2002-11-29 | Fremgangsmåde til at behandle bakterielle infektioner ved anvendelse af gemifloxacin eller et salt deraf og et beta-lactamantibiotikum |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7169792B2 (es) |
| EP (1) | EP1458391B1 (es) |
| AT (1) | ATE372119T1 (es) |
| AU (1) | AU2002360218A1 (es) |
| CA (1) | CA2468036C (es) |
| CY (1) | CY1107038T1 (es) |
| DE (1) | DE60222298T2 (es) |
| DK (1) | DK1458391T3 (es) |
| ES (1) | ES2292844T3 (es) |
| MX (1) | MXPA04005179A (es) |
| NO (1) | NO333196B1 (es) |
| PT (1) | PT1458391E (es) |
| WO (1) | WO2003045390A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011101710A1 (en) * | 2010-02-16 | 2011-08-25 | Wockhardt Research Centre | Efflux pump inhibitors |
| ITMI20080289A1 (it) * | 2008-02-22 | 2009-08-23 | S I F I Societa Industria Farmaceutica Italia | Composizioni di gemifloxacina con elevata efficacia su patologie oculari |
| EP2143422A1 (en) * | 2008-07-11 | 2010-01-13 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections |
| WO2011104981A1 (ja) * | 2010-02-25 | 2011-09-01 | 参天製薬株式会社 | レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤、眼感染症の治療方法、レボフロキサシンもしくはその塩またはそれらの溶媒和物、ならびにその使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3711343A1 (de) * | 1987-04-03 | 1988-10-20 | Bayer Ag | Cephalosporinderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| MA24500A1 (fr) * | 1997-03-21 | 1998-10-01 | Lg Life Sciences Ltd | Derive du sel d'acide carboxylique de naphthyridine . |
| US6576224B1 (en) * | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
-
2002
- 2002-11-29 US US10/496,809 patent/US7169792B2/en not_active Expired - Lifetime
- 2002-11-29 DE DE60222298T patent/DE60222298T2/de not_active Expired - Lifetime
- 2002-11-29 AU AU2002360218A patent/AU2002360218A1/en not_active Abandoned
- 2002-11-29 EP EP02795444A patent/EP1458391B1/en not_active Expired - Lifetime
- 2002-11-29 WO PCT/KR2002/002248 patent/WO2003045390A1/en active IP Right Grant
- 2002-11-29 AT AT02795444T patent/ATE372119T1/de active
- 2002-11-29 MX MXPA04005179A patent/MXPA04005179A/es active IP Right Grant
- 2002-11-29 CA CA002468036A patent/CA2468036C/en not_active Expired - Lifetime
- 2002-11-29 ES ES02795444T patent/ES2292844T3/es not_active Expired - Lifetime
- 2002-11-29 PT PT02795444T patent/PT1458391E/pt unknown
- 2002-11-29 DK DK02795444T patent/DK1458391T3/da active
-
2004
- 2004-06-28 NO NO20042711A patent/NO333196B1/no not_active IP Right Cessation
-
2007
- 2007-11-28 CY CY20071101521T patent/CY1107038T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1458391B1 (en) | 2007-09-05 |
| CA2468036A1 (en) | 2003-06-05 |
| AU2002360218A1 (en) | 2003-06-10 |
| CA2468036C (en) | 2008-01-22 |
| ES2292844T3 (es) | 2008-03-16 |
| MXPA04005179A (es) | 2004-08-11 |
| US7169792B2 (en) | 2007-01-30 |
| PT1458391E (pt) | 2007-12-10 |
| DE60222298T2 (de) | 2008-01-03 |
| DE60222298D1 (de) | 2007-10-18 |
| EP1458391A4 (en) | 2005-05-11 |
| NO20042711L (no) | 2004-06-30 |
| CY1107038T1 (el) | 2012-09-26 |
| EP1458391A1 (en) | 2004-09-22 |
| WO2003045390A1 (en) | 2003-06-05 |
| ATE372119T1 (de) | 2007-09-15 |
| NO333196B1 (no) | 2013-04-02 |
| US20050148571A1 (en) | 2005-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY138285A (en) | Fab i inhibitors | |
| UA88463C2 (ru) | Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции | |
| NO20052362D0 (no) | Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner | |
| NO20025204D0 (no) | Forbindelser og fremgangsmÕter for behandling og forebygging av bakterielle infeksjoner | |
| SE0202598D0 (sv) | Alpha-7 Nicotinic receptor agonists and statins in combination | |
| DE602004012269D1 (de) | Quervernetzte glycopeptid-cephalosporin-antibiotika | |
| DK1037650T3 (da) | Præparater til behandling af Staphylococcus aureus-infektioner | |
| DK1434779T3 (da) | Tværbundne glycopeptid-cephalosporinantibiotika | |
| WO2005046579A3 (en) | Defined dose therapeutic phage | |
| DE602004024393D1 (de) | Quervernetzte glycopeptid-cephalosporin-antibiotika | |
| BR0002577A (pt) | Suspensões orais de trovafloxacina | |
| DK1641436T3 (da) | Inhalerbar aztreonamlysinatformulering til behandling af og forebyggelse mod bakterielle lungeinfektioner | |
| IL162689A0 (en) | Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections | |
| DK1301207T3 (da) | Sammensætninger til behandling af bakterieinfektioner indeholdende en oxazolidinonforbindelse, sulbactam og ampicillin | |
| DE60131085D1 (de) | Antimikrobielle sulfonamide-derivate von lipopeptidantibiotika | |
| CY1107038T1 (el) | Μεθοδος θεραπειας βακτηριακων λοιμωξεων με χρηση της γεμιφλοξασινης ή ενος αλατος αυτης και ενος αντιβιοτικου β-λακταμης | |
| DK1458390T3 (da) | Fremgangsmåde til behandling af bakterielle infektioner ved anvendelse af gemifloxacin eller et salt deraf og et carbapenem antibakterielt middel | |
| DE60137459D1 (de) | Verfahren und zusammensetzungen zur behandlung oder prävention von bakteriellen infektionen | |
| AU2002334761A1 (en) | Methods of treating drug-resistant bacterial infections | |
| CL2004000139A1 (es) | Compuestos derivados de bencimidazol, inhibidores de girasa; composicion farmaceutica; utiles en el tratamiento, prevencion o disminucion de infecciones bacterianas. | |
| IT1304822B1 (it) | Composizione anticrittogamica particolarmente idonea per trattareinfezioni fungine e batteriche delle piante. |